Clinical trials: Volume Status
Emphysema, Pulmonary, Emphysema or COPD
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe.
- Trial name
- CONVERT_II (NCT06035120)
- Testing
- AeriSeal System
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 200 people
- Sponsor
- Pulmonx Corporation
Aortic Valve Stenosis
Detecting Changes in Arterial Blood Volume and Cardiac Efficiency
The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.
- Trial name
- NCT07205341
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- HemoCept Inc.
Emphysema, COPD
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)
This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll up to 140 subjects with severe emphysema and collateral ventilation in the target…
- Conditions
- Emphysema, COPD, Severe Emphysema
- Trial name
- CONVERT (NCT04559464)
- Testing
- AeriSeal, Zephyr Valves
- Where
- 14 sites in Australia, France and 5 more
- Volunteers
- 102 people
- Sponsor
- Pulmonx Corporation
Intensive Care
Measurement of Cardiac Output and Intravascular Volume Status in Children Using COstatus (SH)
Assessment and monitoring of cardiac function in the pediatric intensive care unit (PICU) is an integral part of hemodynamic monitoring of critically ill patients whether it is done directly or indirectly.
- Trial name
- NCT01613859
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Transonic Systems Inc.
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono